TY - JOUR
T1 - Selective Protection by Anguidine of Normal versus Transformed Cells against 1-ß-D-Arabinofuranosylcytosine and Adriamycin
AU - Hromas, Robert
AU - Barlogie, Barthel
AU - Swartzendruber, Douglas
AU - Drewinko, Benjamin
PY - 1983/3/1
Y1 - 1983/3/1
N2 - Anguidine, a protein synthesis inhibitor, has been shown previously to induce a reversible arrest of cell progression through all phases of the mitotic cycle without inducing appreciable cell kill. This “frozen” cell cycle state provided protection of Chinese hamster ovary cells against the lethal effects of 1-ß-D-arabinofuranosylcytosine, Adriamycin, hydroxyurea, 5-fluorouracil, and hyperthermia. We now report on the preferential induction of cytostasis by anguidine in normal WI-38 fibroblasts, occurring at one-tenth of the dosage required to inhibit the cycle progression of WI-38 VA13 cells, the SV40 transformant. Pretreatment with anguidine at a concentration producing effective inhibition of normal cell cycle traverse while permitting sustained proliferation of transformed cells resulted in almost complete protection of WI-38 normal cells against the growth-inhibitory effects of 1-ß-D-arabinofuranosylcytosine and Adriamycin, without reducing the antiproliferative effects of these two agents against WI-38 VA13 transformed cells. Thus, this cytokinetic concept of preferential normal tissue protection should be explored in vivo to increase the therapeutic index of cancer chemotherapy.
AB - Anguidine, a protein synthesis inhibitor, has been shown previously to induce a reversible arrest of cell progression through all phases of the mitotic cycle without inducing appreciable cell kill. This “frozen” cell cycle state provided protection of Chinese hamster ovary cells against the lethal effects of 1-ß-D-arabinofuranosylcytosine, Adriamycin, hydroxyurea, 5-fluorouracil, and hyperthermia. We now report on the preferential induction of cytostasis by anguidine in normal WI-38 fibroblasts, occurring at one-tenth of the dosage required to inhibit the cycle progression of WI-38 VA13 cells, the SV40 transformant. Pretreatment with anguidine at a concentration producing effective inhibition of normal cell cycle traverse while permitting sustained proliferation of transformed cells resulted in almost complete protection of WI-38 normal cells against the growth-inhibitory effects of 1-ß-D-arabinofuranosylcytosine and Adriamycin, without reducing the antiproliferative effects of these two agents against WI-38 VA13 transformed cells. Thus, this cytokinetic concept of preferential normal tissue protection should be explored in vivo to increase the therapeutic index of cancer chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0020697980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020697980&partnerID=8YFLogxK
M3 - Article
C2 - 6825085
AN - SCOPUS:0020697980
SN - 0008-5472
VL - 43
SP - 1135
EP - 1137
JO - Cancer Research
JF - Cancer Research
IS - 3
ER -